Works Cited

1. Guyton A, Hall JE. Textbook of Medical Physiology. 13th ed. Philadelphia, PA: Elsevier; 2016.

2. O'Callaghan C. The Renal System at a Glance. 4th ed. Malden, MA: John Wiley and Sons Ltd.; 2017.

3. Goligorsky MS. Renal Disease: Techniques and Protocols. Totowa, NJ: Humana Press; 2003.

4. Copstead-Kirkhorn LE, Banasik JL. Pathophysiology. 6th ed. St. Louis, MO: Elsevier Health Sciences; 2019.

5. Mitchell R. Pocket Companion to Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, PA: Elsevier; 2017.

6. Avram M, Kiahr S. Renal Disease Progression and Management: Role of Vasoactive Agents, Cytokines, Lipids, and Nutrition. Philadelphia, PA: Elsevier Health Sciences; 1996.

7. Bope T, Kellerman RD. Conn's Current Therapy 2015. Philadelphia, PA: Saunders; 2014.

8. Xin JZ, Laszidk ZG, Nadasdy T, D'Agati VD. Silva's Diagnostic Renal Pathology. 2nd ed. Cambridge: Cambridge University Press; 2018.

9. Berlyne GM. The Kidney Today: Selected Topics in Renal Science. Basel, NY: Karger; 1992.

10. Nowak T. Pathophysiology: Concepts and Applications for Health Care Professionals. 2nd ed. Boston, MA: McGraw-Hill; 1999.

11. Rennke H, Denton M, Magee C. Renal Disease: Prevention and Treatment. New York, NY: CRC Press; 1998.

12. Johnson G. On the Diseases of the Kidney, Their Pathology, Diagnosis, and Treatment. London: J.W. Parker and Son; 1852.

13. Clark WB. The Diagnosis and Treatment of Diseases of the Kidney Amenable to Direct Surgical Interference. London: Lewis Publishing; 1886.

14. Wilcox CS. Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's The Kidney. 3rd ed. Philadelphia, PA: Saunders/Elsevier; 2008.

15. Moorthy V. Pathophysiology of Kidney Disease and Hypertension. Philadephia, PA: Elsevier Health Sciences; 2009.

16. Brenner BM, Coe FL, Rector FC. Renal Physiology in Health and Disease. Philadelphia, PA: Elsevier Health Sciences; 1987.

17. Gonick HC, Buckalew VM. Renal Tubular Disorders: Pathophysiology, Diagnosis and Management. New York, NY: Marcel Dekker; 1985.

18. Avram MM. Improving Prognosis for Kidney Disorders. Dordrecht: Springer Press; 2011.

19. Burton DR. Pathophysiology of Renal Disease. 2nd ed. New York, NY: McGraw-Hill; 1987.

20. McCance KL, Felver L. Pathophysiology: The Biologic Basis for Disease in Adults and Children. 8th ed. St. Louis, MO: Elsevier Health Sciences; 2018.

21. Schrier RW. Renal and Electrolyte Disorders. 8th ed. Philadelphia, PA: Wolters Kluwer; 2018.

22. Humes HD. Pathophysiology of Electrolyte and Renal Disorders. New York, NY: Churchill Livingstone; 1986.

23. Tisher CC, Brenner BM. Renal Pathology with Clinical and Functional Correlations. 2nd ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 1994.

24. Price SA. Pathophysiology: Clinical Concepts of Disease Processes. 7th ed. St. Louis, MO: Mosby; 2014.

25. Nahikian-Nelms M. Nutrition Therapy and Pathophysiology. 4th ed. Boston, MA: Cengage; 2020.

26. Brashers VL. Clinical Applications of Pathophysiology: Assessment, Diagnostic Reasoning and Management. 2nd ed. St. Louis, MO: Mosby; 2002.

27. Black J, Hawks JH, Keene AM. Medical Surgical Nursing: Clinical Management for Continuity of Care. 8th ed. Philadelphia, PA: W.B Saunders, 2011.

28. LeMone P, Burke KM, Bauldoff G. Medical-Surgical Nursing: Critical Thinking in Patient Care. 5th ed. Upper Saddle River, NJ: Prentice Hall; 2014.

29. Ginès P. Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. Walden, MA: Blackwell; 2005.

30. Suki WN, Eknoyan G. The Kidney in Systemic Disease. New York, NY: Wiley, John and Sons, Inc.; 1981.

31. Buttaro TM. Primary Care: A Collaborative Practice. 5th ed. St. Louis, MO: Elsevier; 2017.

32. Al-Shaikh TM, Alkaseb KS, Mudawi MME, Yassin AYA, Habeballa RS, Alzain SD. Toxicological studies on commercial hair dye brand commonly used in Saudi Arabia: histological study of the liver, kidney, heart, and testis. J Basic Appl Zoology. 2018;79:22.

33. Ackley BJ, Ladwig GB, Flynn Makic MB, Martinez-Kratz MR, Zanotti M. Nursing Diagnosis Handbook: An Evidence-Based Guide to Planning Care. 12th ed. St. Louis, MO: Elsevier; 2020.

34. Ladwig GE, Ackley BJ, Flynn Makic MB, Martinez-Kratz MR, Zanotti M. Mosby's Guide to Nursing Diagnosis. 6th ed. St. Louis, MO: Elsevier; 2020.

35. Ehrman JK. Clinical Exercise Physiology. 4th ed. Champaign, IL: Human Kinetics; 2019.

36. Zerwekh, JG, Claborn JC, Gaglione T, Gameau AZ, Souter S. Mosby's Pharmacology Memory NoteCards: Visual, Mnemonic, and Memory Aids for Nurses. 3rd ed. Philadelphia, PA: Elsevier Mosby; 2011.

37. Mount DB, Pollak MR. Molecular and Genetic Basis of Renal Disease. Philadelphia, PA: Elsevier Health Sciences; 2008.

38. Barkauskas VH. Health and Physical Assessment. 3rd ed. St. Louis, MO: Mosby; 2002.

39. Coleman B. Safe Clinical Use of Fluoroscopy. Sacramento, CA: NetCE; 2019.

40. McDougal WS, Wein AJ, Kavoussi LR, Partin AW, Peters C. Campbell-Walsh Urology 11th Edition Review. 2nd ed. Philadelphia, PA: Elsevier; 2015.

41. Bihl GR, Petri M, Fine DM. Kidney biopsy in lupus nephritis: look before you leap. Nephrol Dial Transplant. 2006;21(7):1749-1752.

42. Blake MA, Sweeney AT. Pheochromocytoma. Available at https://emedicine.medscape.com/article/124059-overview. Last accessed August 6, 2020

43. Ferrell BR, Paice JA. Oxford Textbook of Palliative Nursing. 5th ed. New York, NY: Oxford University Press; 2019.

44. Levine DZ. Caring for the Renal Patient. 3rd ed. Philadelphia, PA: Saunders; 1997.

45. Lederer E, Alsauskas ZC, Mackelaite L, Nayak V. Hyperkalemia. Available at https://emedicine.medscape.com/article/240903-overview. Last accessed August 6, 2020.

46. Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS. Harrison's Principles of Internal Medicine. 19th ed. New York, NY: McGraw-Hill; 2015.

47. Mandal AK. Hypokalemia and hyperkalemia. Med Clin North Am. 1997;81(3):611-639.

48. Lexicomp Online. Available at https://online.lexi.com. Last accessed August 6, 2020.

49. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010;21(5):733-735.

50. Tamargo J. New Drugs for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors: Hype or Hope? Available at https://www.discoverymedicine.com/Juan-Tamargo/2014/11/new-drugs-for-the-treatment-of-hyperkalemia-in-patients-treated-with-renin-angiotensin-aldosterone-system-inhibitors-hype-or-hope. Last accessed August 6, 2020.

51. Hollander-Rodriguez JC, Calvert JF. Hyperkalemia. Am Fam Physician. 2006;73(2):283-290.

52. DiPiro JT. Pharmacotherapy A Pathophysiologic Approach. 11th ed. New York, NY: McGraw Hill Medical; 2020.

53. Longo DL, Kasper DL, Jameson JL, et al. Harrison's Principles of Internal Medicine. 19th ed. New York, New York: McGraw-Hill; 2015.

54. Malhotra D, Tzamaloukas AH. Non-dialysis management of chronic renal failure. Med Clin North Am. 1997;81(3):749-766.

55. Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL. Brenner and Rector's The Kidney. 10th ed. Philadelphia, PA: Saunders; 2015.

56. International Society of Nephrology. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf. Last accessed August 6, 2020.

57. NKF KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Available at https://www.kidney.org/sites/default/files/docs/ckd_evaluation_classification_stratification.pdf. Last accessed August 6, 2020.

58. Centers for Medicare and Medicaid Services. Medicare Coverage of Kidney Dialysis and Kidney Transplant Services. Available at https://www.medicare.gov/Pubs/pdf/10128-Medicare-Coverage-ESRD.pdf. Last accessed November 5, 2018.

59. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet, 2017. Atlanta, GA: US Department of Health and Human Services; 2017.

60. Bullock A, Burrows NR, Narva AS, et al. Vital signs: decrease in incidence of diabetes-related end-stage renal disease among American Indians/Alaska Natives—United States, 1996–2013. MMWR. 2017;66(01):26-32.

61. Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care. 2010;33(1):73-77.

62. Whaley-Connell AT, Vassalotti JA, Collins AJ, Chen SC, McCullough PA. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2011: executive summary. Am J Kidney Dis. 2012;59(3 Suppl 2):S1-S4.

63. United States Renal Data System Annual Data Report 2018: Epidemiology of Kidney Disease in the United States. Available at https://www.usrds.org/adr.aspx. Last accessed August 6, 2020.

64. Gross ML, Dikow R, Ritz E. Diabetic nephropathy: recent insights into the pathophysiology and the progression of diabetic nephropathy. Kidney Int. 2005;(94):S50-S53.

65. Shumway JT, Gambert SR. Diabetic nephropathy: pathophysiology and management. Int Urol Nephrol. 2002;34(2):257-264.

66. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.

67. Jones J, Holmen J, De Graauw J, Jovanovich A, Thornton S, Chonchol M. Association of complete recovery from acute kidney injury with incident CKD stage 3 and all-cause mortality. Am J Kidney Dis. 2012;60(3):402-408.

68. Hart PD, Bakris GL. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010;11(16):2675-2686.

69. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631-1634.

70. Portolés J, Gorriz JL, Rubio E, et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013;14:2.

71. National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.Am J Kidney Dis. 2003;42(Suppl 3):S1-S201.

72. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin Am J Soc Nephrol. 2012;7(8):1234-1241.

73. Block GA, Ix JH, Ketteler M, et al. Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis. 2013;62(3):457-473.

74. Lanken PN, Terry PB, Delisser HM, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med. 2008;177(8):912-927.

75. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.

76. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1-S266.

77. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:1-150.

78. American Dietetic Association. Manual of Clinical Dietetics. 6th ed. Chicago, IL: Academy of Nutrition and Dietetics; 2000.

79. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 2002;17(1):S29-S36.

80. Workeneh BT, Agraharkar M, Gupta R. Acute Kidney Injury. Available at https://emedicine.medscape.com/article/243492-overview. Last accessed August 6, 2020.

81. Huether SE, McCance KL, Brashers VL. Understanding Pathophysiology. 7th ed. St. Louis, MO: Elsevier; 2020.

82. Bullock BA. Focus on Pathophysiology. 4th ed. Philadelphia, PA: Lippincott; 2000.

83. Baird MS. Manual ofCritical Care Nursing: Nursing Interventions and Collaborative Management. 7th ed. St. Louis, MO: Mosby; 2016.

84. Norris TL. Porth's Pathophysiology: Concepts of Altered Health States. 10th ed. Philadelphia, PA: Wolters Kluwer; 2019.

85. National Institute of Diabetes and Digestive and Kidney Diseases. National Kidney Disease Education Program. Available at https://www.niddk.nih.gov/health-information/community-health-outreach/information-clearinghouses/nkdep. Last accessed June 23, 2020.

86. Miller MJ. Kidney Disorders. New York, NY: Chelsea House; 1992.

87. Bruyere HJ Jr. 100 Case Studies in Pathophysiology. Philadelphia, PA: Lippincott, Williams and Wilkins: 2009.

88. Berg SM, Bittner EA, Lee J. Massachusetts General Hospital Review of Critical Care Medicine. Philadelphia, PA: Wolters, Kluwer, Lippincott, Williams & Wilkins; 2014.

89. American Cancer Society. Key Statistics About Kidney Cancer. Available at https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html. Last accessed August 6, 2020.

90. Smith S. Kidney Cancer: Causes, Symptoms, Signs, Diagnosis, Treatments, Stages of Kidney Cancer. Charleston, SC: CreateSpace; 2012.

91. American Cancer Society. Key Statistics About Bladder Cancer. Available at https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html. Last accessed August 6, 2020.

92. National Cancer Institute. Bladder Cancer Treatment (PDQ)–Health Professional Version. Available at https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq. Last accessed August 6, 2020.

93. Galvagno SM. Emergency Pathophysiology: Clinical Applications for Prehospital Care. Jackson, WY: Teton NewMedia; 2013.

94. Zane RD. Pocket Emergency Medicine. Philadelphia, PA: Wolters Kluwer; 2018.

95. Markovchick VJ, Pons PT, Bakes KM, Buchanan JA. Emergency Medicine Secrets. 6th ed. Philadelphia, PA: Elsevier; 2016.

96. Goldstein RS. Mechanisms of Injury in Renal Disease and Toxicity. Boca Raton, FL: CRC Press; 1994.

97. KDOQI Clinical Practice Guidelines for vascular access. Am J Kidney Dis. 2006;48(Suppl 1):S176-S247.

98. Beathard G. A practitioner's resource guide to hemodialysis arteriovenous fistulas. ESRD Network of Texas. 2003;(Suppl).

99. Lomonte C, Basile C. Preoperative assessment and planning of hemodialysis vascular access. Clin Kidney J. 2015;8(3):278-281.

100. Santoro D, Benedetto F, Mondello P, et al. Vascular access for hemodialysis: current perspectives. Int J Nephrol Renovasc Dis. 2014;7:284-294.

101. Drew DA, Lok CE. Strategies for planning the optimal dialysis access for an individual patient. Curr Opin Nephrol Hypertens. 2014;23(3):314-320.

102. Tordoir JH, Bode AS, van Loon MM. Preferred strategy for hemodialysis in access creation in elderly patients. Eur J Vasc Endovasc Surg. 2015;49(6):738-743.

103. Mansilla AV, Toombs BD, Vaughn WK, Zeledon JI. Patency and life-spans of failing hemodialysis grafts in patients undergoing repeated percutaneous de-clotting. Tex Heart Inst J. 2001;28(4):249-253.

104. Zaleski G. Declotting, maintenance, and avoiding procedural complications of native arteriovenous fistulae. Semin Intervent Radiol. 2004;21(2):83-93.

105. Centers for Medicare and Medicaid Services. Center for Clinical Standards and Quality. CMS ESRD Measured Manual for the 2018 Performance Period/2020 Payment Year v3.0. Available at https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/ESRDQIP/Downloads/ESRD-Manual-v30.pdf. Last accessed August 6, 2020.

106. Hagen SM, Lafranca JA, Ijzemans JN, Dor FJ. A systematic review and meta-analysis of the influence of peritoneal dialysis catheter type on complication rate and catheter survival. Kidney Int. 2014;85(4):920-932.

107. Lye WC, Kour NW, van der Straaten JC, Leong SO, Lee EJ. A prospective randomized comparison of the Swan neck, coiled, and straight Tenckhoff catheters in patients on CAPD. Perit Dial Int. 1996;16(Suppl 1):S333-S335.

108. Xie J, Kiryluk K, Ren H, et al. Coiled versus straight peritoneal dialysis catheters: a randomized controlled trial and meta-analysis. Am J Kidney Dis. 2011;58(6):946-955.

109. National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Disease Statistics for the United States. Available at https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. Last accessed August 6, 2020.

110. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004-2014.

111. Organ Procurement and Transplantation Network. Policies: Allocation of Kidneys. Available at https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf. Last accessed August 6, 2020.

112. Organ Procurement and Transplantation Network. Kidney Allocation System. Available at https://optn.transplant.hrsa.gov/learn/professional-education/kidney-allocation-system. Last accessed August 6, 2020.

113. Tapiawala SN, Tinckam KJ, Cardella CJ, et al. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol. 2010;21(1):153-161.

114. Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J. 2008;32(3):796-803.

115. Renal Physicians Association. Shared Decision-Making in the Appropriate Initiation and Withdrawal from Dialysis. Clinical Practice Guideline. 2nd ed. Rockville, MD: Renal Physicians Association; 2010.

116. Larson AM, Curtis JR. Integrating palliative care for liver transplant candidates: "too well for transplant, too sick for life." JAMA. 2006;295(108):2168-2176.

117. McCusker M, Ceronsky L, Crone C, et al. Institute for Clinical Systems Improvement. Palliative Care for Adults. Available at https://www.icsi.org/_asset/k056ab/PalliativeCare.pdf. Last accessed August 6, 2020.

118. Clayton JM, Hancock KM, Butow PN, et al. Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers. Med J Aust. 2007;188(12 Suppl):S77, S79, S83-S108.

119. Buckman R. Communication skills in palliative care: a practical guide. Neurol Clin. 2001;19(4):989-1004.

120. Finlay E, Casarett D. Making difficult decisions easier: using prognosis to facilitate transitions to hospice. Ca Cancer J Clin. 2009;59:250-263.

121. Stapleton R, Curtis JR. End-of-life considerations in older patients who have lung disease. Clin Chest Med. 2007;28(4):801-811.

122. Silveira MJ, Kim SY, Langa KM. Advance directives and outcomes of surrogate decision making before death. N Engl J Med. 2010;362(13):1211-1218.

123. Goodlin SJ. Palliative care in congestive heart failure. J Am Coll Cardiol. 2009;54(5):386-396.

Evidence-Based Practice Recommendations Citations

1. Management of Chronic Kidney Disease Working Group. VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care. Washington, DC: Department of Veterans Affairs, Department of Defense; 2014. Available at https://www.healthquality.va.gov/guidelines/CD/ckd/VADoDCKDCPG2014.pdf. Last accessed August 14, 2020.

2. American Dietetic Association. Chronic Kidney Disease Evidence-Based Nutrition Practice Guideline. Chicago, IL: American Dietetic Association; 2010. Available at https://www.andeal.org/topic.cfm?cat=3927. Last accessed August 14, 2020.

3. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77(4):299-311. Available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf. Last accessed August 14, 2020.


Copyright © 2020 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.